Comparative effectiveness and pharmacological fingerprints of indobufen versus rivaroxaban in patients with chronic kidney disease: a single-center, real-world study.

Front Pharmacol · 2025 · PMC12672237 · PMID 41347166

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Conversely, PDW (59.0%) and Antithrombin III (88.9%) showed an increasing trend.

also in 63,971 other papers

a decreasing trendno p-value reported

In the rivaroxaban group ( Figure 6A ), a decreasing trend was observed for parameters including MPV (72.7%), FIB (75.0%), FDP (77.8%), D-Dimer (66.7%), and APTT (65.0%).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.